Search Results - "Antill, Yoland"

Exome sequencing identifies rare deleterious mutations in DNA repair genes FANCC and BLM as potential breast cancer susceptibility alleles by Thompson, Ella R, Doyle, Maria A, Ryland, Georgina L, Rowley, Simone M, Choong, David Y H, Tothill, Richard W, Thorne, Heather, Barnes, Daniel R, Li, Jason, Ellul, Jason, Philip, Gayle K, Antill, Yoland C, James, Paul A, Trainer, Alison H, Mitchell, Gillian, Campbell, Ian G

“…Despite intensive efforts using linkage and candidate gene approaches, the genetic etiology for the majority of families with a multi-generational breast…”
Get full text

Exercise as a diagnostic and therapeutic tool for the prevention of cardiovascular dysfunction in breast cancer patients by Howden, Erin J, Bigaran, Ashley, Beaudry, Rhys, Fraser, Steve, Selig, Steve, Foulkes, Steve, Antill, Yoland, Nightingale, Sophie, Loi, Sherene, Haykowsky, Mark J, La Gerche, André

“…Background Anthracycline chemotherapy may be associated with decreased cardiac function and functional capacity measured as the peak oxygen uptake during…”
Get full text

Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial by Antill, Yoland, Kok, Peey-Sei, Robledo, Kristy, Yip, Sonia, Cummins, Michelle, Smith, Deborah, Spurdle, Amanda, Barnes, Elizabeth, Lee, Yeh Chen, Friedlander, Michael, Baron-Hay, Sally, Shannon, Catherine, Coward, Jermaine, Beale, Philip, Goss, Geraldine, Meniawy, Tarek, Lombard, Janine, Andrews, John, Stockler, Martin R, Mileshkin, Linda

“…BackgroundIn this study, we assessed the activity of durvalumab, an antibody to programmed death ligand-1, in two cohorts of women with advanced endometrial…”
Get full text

Cancer Risks for MLH1 and MSH2 Mutation Carriers by Dowty, James G., Win, Aung K., Buchanan, Daniel D., Lindor, Noralane M., Macrae, Finlay A., Clendenning, Mark, Antill, Yoland C., Thibodeau, Stephen N., Casey, Graham, Gallinger, Steve, Marchand, Loic Le, Newcomb, Polly A., Haile, Robert W., Young, Graeme P., James, Paul A., Giles, Graham G., Gunawardena, Shanaka R., Leggett, Barbara A., Gattas, Michael, Boussioutas, Alex, Ahnen, Dennis J., Baron, John A., Parry, Susan, Goldblatt, Jack, Young, Joanne P., Hopper, John L., Jenkins, Mark A.

“…ABSTRACT We studied 17,576 members of 166 MLH1 and 224 MSH2 mutation‐carrying families from the Colon Cancer Family Registry. Average cumulative risks of…”
Get full text

Breast cancer polygenic risk scores: a 12-month prospective study of patient reported outcomes and risk management behavior by Yanes, Tatiane, Meiser, Bettina, Kaur, Rajneesh, Young, Mary-Anne, Mitchell, Philip B., Scheepers-Joynt, Maatje, McInerny, Simone, Taylor, Shelby, Barlow-Stewart, Kristine, Antill, Yoland, Salmon, Lucinda, Smyth, Courtney, Betz-Stablein, Brigid, James, Paul A.

“…Purpose To prospectively assess patient reported outcomes and risk management behavior of women choosing to receive (receivers) or decline (decliners) their…”
Get full text

Pilot study of an online training program to increase genetic literacy and communication skills in oncology healthcare professionals discussing BRCA1/2 genetic testing with breast and ovarian cancer patients by Meiser, Bettina, Woodward, Paula, Gleeson, Margaret, Kentwell, Maira, Fan, Helen Mar, Antill, Yoland, Butow, Phyllis N., Boyle, Frances, Best, Megan, Taylor, Natalie, Bell, Katy, Tucker, Kathy

“…The increasing use of genetic testing for BRCA1/2 and other pathogenic variants in the management of women with breast and ovarian cancer necessitates…”
Get full text

Enhanced Toxicity With Trastuzumab Emtansine And Concurrent Adjuvant Radiotherapy: Non-Consecutive Case Series by Soo, Jade, Byrne, Keelan, White, Michelle, Antill, Yoland, Taylor, Karen, Tan, Jennifer, Tran, Phillip, David, Steven

Get full text

Risks of Lynch Syndrome Cancers for MSH6 Mutation Carriers by Baglietto, Laura, Lindor, Noralane M., Dowty, James G., White, Darren M., Wagner, Anja, Gomez Garcia, Encarna B., Vriends, Annette H. J. T., Cartwright, Nicola R., Barnetson, Rebecca A., Farrington, Susan M., Tenesa, Albert, Hampel, Heather, Buchanan, Daniel, Arnold, Sven, Young, Joanne, Walsh, Michael D., Jass, Jeremy, Macrae, Finlay, Antill, Yoland, Winship, Ingrid M., Giles, Graham G., Goldblatt, Jack, Parry, Susan, Suthers, Graeme, Leggett, Barbara, Butz, Malinda, Aronson, Melyssa, Poynter, Jenny N., Baron, John A., Le Marchand, Loic, Haile, Robert, Gallinger, Steve, Hopper, John L., Potter, John, de la Chapelle, Albert, Vasen, Hans F., Dunlop, Malcolm G., Thibodeau, Stephen N., Jenkins, Mark A.

“…Background Germline mutations in MSH6 account for 10%–20% of Lynch syndrome colorectal cancers caused by hereditary DNA mismatch repair gene mutations. Because…”
Get full text

Exercise as a diagnostic and therapeutic tool for preventing cardiovascular morbidity in breast cancer patients- the BReast cancer EXercise InTervention (BREXIT) trial protocol by Foulkes, Stephen J, Howden, Erin J, Antill, Yoland, Loi, Sherene, Salim, Agus, Haykowsky, Mark J, Daly, Robin M, Fraser, Steve F, La Gerche, Andre

“…Anthracycline chemotherapy (AC) is an efficacious (neo) adjuvant treatment for early-stage breast cancer (BCa), but is associated with an increased risk of…”
Get full text

Denosumab: Prevention and management of hypocalcemia, osteonecrosis of the jaw and atypical fractures by Pittman, Kenneth, Antill, Yoland C, Goldrick, Amanda, Goh, Jeffrey, Boer, Richard H

“…Denosumab, a bone‐modifying agent, reduces the risk of skeletal‐related events in patients with bone metastases from solid tumors and is generally well…”
Get full text

A tumor focused approach to resolving the etiology of DNA mismatch repair deficient tumors classified as suspected Lynch syndrome by Walker, Romy, Mahmood, Khalid, Joo, Jihoon E, Clendenning, Mark, Georgeson, Peter, Como, Julia, Joseland, Sharelle, Preston, Susan G, Antill, Yoland, Austin, Rachel, Boussioutas, Alex, Bowman, Michelle, Burke, Jo, Campbell, Ainsley, Daneshvar, Simin, Edwards, Emma, Gleeson, Margaret, Goodwin, Annabel, Harris, Marion T, Henderson, Alex, Higgins, Megan, Hopper, John L, Hutchinson, Ryan A, Ip, Emilia, Isbister, Joanne, Kasem, Kais, Marfan, Helen, Milnes, Di, Ng, Annabelle, Nichols, Cassandra, O'Connell, Shona, Pachter, Nicholas, Pope, Bernard J, Poplawski, Nicola, Ragunathan, Abiramy, Smyth, Courtney, Spigelman, Allan, Storey, Kirsty, Susman, Rachel, Taylor, Jessica A, Warwick, Linda, Wilding, Mathilda, Williams, Rachel, Win, Aung K, Walsh, Michael D, Macrae, Finlay A, Jenkins, Mark A, Rosty, Christophe, Winship, Ingrid M, Buchanan, Daniel D

“…Routine screening of tumors for DNA mismatch repair (MMR) deficiency (dMMR) in colorectal (CRC), endometrial (EC) and sebaceous skin (SST) tumors leads to a…”
Get full text

Psychological outcomes and surgical decisions after genetic testing in women newly diagnosed with breast cancer with and without a family history by Meiser, Bettina, Quinn, Veronica F, Mitchell, Gillian, Tucker, Kathy, Watts, Kaaren J, Rahman, Belinda, Peate, Michelle, Saunders, Christobel, Geelhoed, Elizabeth, Gleeson, Margaret, Barlow-Stewart, Kristine, Field, Michael, Harris, Marion, Antill, Yoland C, Susman, Rachel, Bowen, Michael T, Mills, Llew, Kirk, Judy

“…In patients with early breast cancer, personal and tumour characteristics other than family history are increasingly used to prompt genetic testing to guide…”
Get full text

Streamlined genetic education is effective in preparing women newly diagnosed with breast cancer for decision making about treatment-focused genetic testing: a randomized controlled noninferiority trial by Quinn, Veronica F., Meiser, Bettina, Kirk, Judy, Tucker, Kathy M., Watts, Kaaren J., Rahman, Belinda, Peate, Michelle, Saunders, Christobel, Geelhoed, Elizabeth, Gleeson, Margaret, Barlow-Stewart, Kristine, Field, Michael, Harris, Marion, Antill, Yoland C., Cicciarelli, Linda, Crowe, Karen, Bowen, Michael T., Mitchell, Gillian

“…Increasingly, women newly diagnosed with breast cancer are being offered treatment-focused genetic testing (TFGT). As the demand for TFGT increases,…”
Get full text

PARAGON (ANZGOG-0903): a phase 2 study of anastrozole in asymptomatic patients with estrogen and progesterone receptor-positive recurrent ovarian cancer and CA125 progression by Kok, Peey Sei, Beale, Philip, O'Connell, Rachel L, Grant, Peter, Bonaventura, Tony, Scurry, James, Antill, Yoland, Goh, Jeffrey, Sjoquist, Katrin, DeFazio, Anna, Mapagu, Cristina, Amant, Frederic, Friedlander, Michael

“…A subset of patients with recurrent ovarian cancer (ROC) may benefit from antiestrogen therapy with higher response rates reported in tumors that are strongly…”
Get full text

Identifying primary and secondary MLH1 epimutation carriers displaying low-level constitutional MLH1 methylation using droplet digital PCR and genome-wide DNA methylation profiling of colorectal cancers by Joo, Jihoon E, Mahmood, Khalid, Walker, Romy, Georgeson, Peter, Candiloro, Ida, Clendenning, Mark, Como, Julia, Joseland, Sharelle, Preston, Susan, Graversen, Lise, Wilding, Mathilda, Field, Michael, Lemon, Michelle, Wakeling, Janette, Marfan, Helen, Susman, Rachel, Isbister, Joanne, Edwards, Emma, Bowman, Michelle, Kirk, Judy, Ip, Emilia, McKay, Lynne, Antill, Yoland, Hopper, John L, Boussioutas, Alex, Macrae, Finlay A, Dobrovic, Alexander, Jenkins, Mark A, Rosty, Christophe, Winship, Ingrid M, Buchanan, Daniel D

“…MLH1 epimutation is characterised by constitutional monoallelic MLH1 promoter hypermethylation, which can cause colorectal cancer (CRC). Tumour molecular…”
Get full text

Lynch syndrome and cervical cancer by Antill, Yoland C., Dowty, James G., Win, Aung Ko, Thompson, Tina, Walsh, Michael D., Cummings, Margaret C., Gallinger, Steven, Lindor, Noralane M., Le Marchand, Loïc, Hopper, John L., Newcomb, Polly A., Haile, Robert W., Church, James, Tucker, Katherine M., Buchanan, Daniel D., Young, Joanne P., Winship, Ingrid M., Jenkins, Mark A.

“…Carriers of germline mutations in DNA mismatch repair (MMR) genes are at increased risk of several cancers including colorectal and gynecologic cancers (Lynch…”
Get full text

Therapeutic options for mucinous ovarian carcinoma by Gorringe, Kylie L., Cheasley, Dane, Wakefield, Matthew J., Ryland, Georgina L., Allan, Prue E., Alsop, Kathryn, Amarasinghe, Kaushalya C., Ananda, Sumitra, Bowtell, David D.L., Christie, Michael, Chiew, Yoke-Eng, Churchman, Michael, DeFazio, Anna, Fereday, Sian, Gilks, C. Blake, Gourley, Charlie, Hadley, Alison M., Hendley, Joy, Hunter, Sally M., Kaufmann, Scott H., Kennedy, Catherine J., Köbel, Martin, Le Page, Cecile, Li, Jason, Lupat, Richard, McNally, Orla M., McAlpine, Jessica N., Pyman, Jan, Rowley, Simone M., Salazar, Carolina, Saunders, Hugo, Semple, Timothy, Stephens, Andrew N., Thio, Niko, Torres, Michelle C., Traficante, Nadia, Zethoven, Magnus, Antill, Yoland C., Campbell, Ian G., Scott, Clare L.

“…Mucinous ovarian carcinoma (MOC) is an uncommon ovarian cancer histotype that responds poorly to conventional chemotherapy regimens. Although long overall…”
Get full text

Exercise Attenuates Cardiotoxicity of Anthracycline Chemotherapy Measured by Global Longitudinal Strain by Costello, Benedict T., Roberts, Timothy J., Howden, Erin J., Bigaran, Ashley, Foulkes, Steven J., Beaudry, Rhys I., Janssens, Kristel, Haykowsky, Mark J., Antill, Yoland, Nightingale, Sophie, Loi, Sherene, La Gerche, Andre

Get full text

Gene Methylation in Breast Ductal Fluid from BRCA1 and BRCA2 Mutation Carriers by ANTILL, Yoland C, MITCHELL, Gillian, JOHNSON, Sandra A, DEVEREUX, Lisa, MILNER, Alvin, DI IULIO, Juliana, LINDEMAN, Geoffrey J, KIRK, Judy, PHILLIPS, Kelly Anne, CAMPBELL, Ian G

“…Purpose: Genomic alterations (including gene hypermethylation) are likely to precede the phenotypic changes associated with breast tumorigenesis. From a…”
Get full text

Loss of Heterozygosity at the BRCA2 Locus Detected by Multiplex Ligation-Dependent Probe Amplification is Common in Prostate Cancers from Men with a Germline BRCA2 Mutation by Willems, Amber J, Dawson, Sarah-Jane, Samaratunga, Hema, De Luca, Alessandro, Antill, Yoland C, Hopper, John L, Thorne, Heather J

“…Purpose: Prostate cancer risk is increased for men carrying a pathogenic germline mutation in BRCA2 , and perhaps BRCA1. Our primary aim was to test for loss…”
Get full text